Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Aug 8, 23 | 0.28 Increased by +212.00% | 0.36 Decreased by -22.22% |
May 9, 23 | -0.28 Decreased by -21.74% | -0.33 Increased by +15.15% |
Mar 27, 23 | -0.32 Increased by +23.81% | -0.25 Decreased by -28.00% |
Nov 14, 22 | -0.26 Decreased by -160.00% | -0.23 Decreased by -13.04% |
Aug 15, 22 | -0.25 Increased by +96.84% | -0.24 Decreased by -4.17% |
May 16, 22 | -0.23 | -0.17 Decreased by -35.29% |
Mar 28, 22 | -0.42 | -0.14 Decreased by -200.00% |
Nov 15, 21 | -0.10 | -0.17 Increased by +41.18% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jun 30, 23 | 0.00 Decreased by N/A% | -11.61 M Decreased by -17.38% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0.00 Decreased by N/A% | -9.48 M Decreased by -4.72% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | 0.00 Decreased by N/A% | -13.86 M Decreased by -67.38% | Decreased by N/A% Decreased by N/A% |
Sep 30, 22 | 0.00 Decreased by N/A% | -10.05 M Decreased by -161.28% | Decreased by N/A% Decreased by N/A% |
Jun 30, 22 | 0.00 Decreased by N/A% | -9.89 M Increased by +91.71% | Decreased by N/A% Decreased by N/A% |
Mar 31, 22 | 0.00 Decreased by N/A% | -9.05 M Increased by +81.97% | Decreased by N/A% Decreased by N/A% |
Dec 31, 21 | 0.00 Decreased by -100.00% | -8.28 M Decreased by -4.80 K% | Decreased by N/A% Decreased by N/A% |
Sep 30, 21 | 0.00 Decreased by -100.00% | -3.85 M Decreased by -54.46% | Decreased by N/A% Decreased by N/A% |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.